ATE290591T1 - Für adseverin kodierendes gen - Google Patents

Für adseverin kodierendes gen

Info

Publication number
ATE290591T1
ATE290591T1 AT95903966T AT95903966T ATE290591T1 AT E290591 T1 ATE290591 T1 AT E290591T1 AT 95903966 T AT95903966 T AT 95903966T AT 95903966 T AT95903966 T AT 95903966T AT E290591 T1 ATE290591 T1 AT E290591T1
Authority
AT
Austria
Prior art keywords
adseverin
base sequence
seq
animal
amino acid
Prior art date
Application number
AT95903966T
Other languages
English (en)
Inventor
Seiji Nakamura
Takashi Sakurai
Jun-Ichi Nezu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE290591T1 publication Critical patent/ATE290591T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
AT95903966T 1993-12-28 1994-12-27 Für adseverin kodierendes gen ATE290591T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP35511293 1993-12-28
JP16023694 1994-07-12
JP34069294A JP3914272B2 (ja) 1993-12-28 1994-12-20 アドゼベリンをコードする遺伝子
PCT/JP1994/002227 WO1995018221A1 (fr) 1993-12-28 1994-12-27 Gene codant pour les adseverines

Publications (1)

Publication Number Publication Date
ATE290591T1 true ATE290591T1 (de) 2005-03-15

Family

ID=27321664

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903966T ATE290591T1 (de) 1993-12-28 1994-12-27 Für adseverin kodierendes gen

Country Status (9)

Country Link
US (3) US6130060A (de)
EP (2) EP1371728A1 (de)
JP (1) JP3914272B2 (de)
AT (1) ATE290591T1 (de)
AU (1) AU1281495A (de)
CA (1) CA2180103C (de)
DE (1) DE69434292T2 (de)
TW (1) TW438886B (de)
WO (1) WO1995018221A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
AU7737196A (en) * 1996-11-14 1998-06-03 Brigham And Women's Hospital Polyphosphoinositide binding peptides for intracellular drug delivery
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP2335722B1 (de) * 2004-05-12 2019-03-13 The Brigham and Women's Hospital, Inc. Verwendung von Gelsolin zur Behandlung von Infektionen
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8058252B2 (en) * 2005-12-30 2011-11-15 Institut Gustave Roussy Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors
US8440622B2 (en) 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
DK3279663T3 (da) 2006-03-15 2021-10-18 Brigham & Womens Hospital Inc Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
EP2188309A4 (de) * 2007-08-15 2011-03-30 Mountgate Group Ltd Gelsolinbindungsmittelzusammensetzungen und anwendungen davon
US9575072B2 (en) * 2008-01-25 2017-02-21 The Brigham And Women's Hospital, Inc. Diagnostic and therapeutic uses of gelsolin in renal failure
CN101955528B (zh) * 2010-08-05 2012-07-04 许爱娥 人mchr1抗原表位区基因表达相关蛋白mchr1-c及其编码基因
CN102766194B (zh) * 2011-05-03 2016-04-06 中国医学科学院医药生物技术研究所 具有hiv-1蛋白酶抑制活性的寡肽化合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69130289T2 (de) * 1990-04-11 1999-06-02 Brigham And Women's Hospital, Boston, Mass. Therapeutische verwendung von actin-bindenden verbindungen

Also Published As

Publication number Publication date
AU1281495A (en) 1995-07-17
DE69434292T2 (de) 2006-01-12
DE69434292D1 (de) 2005-04-14
JPH0880195A (ja) 1996-03-26
CA2180103C (en) 2005-02-08
US6184352B1 (en) 2001-02-06
EP0756005A1 (de) 1997-01-29
US6271353B1 (en) 2001-08-07
WO1995018221A1 (fr) 1995-07-06
EP1371728A1 (de) 2003-12-17
TW438886B (en) 2001-06-07
EP0756005B1 (de) 2005-03-09
EP0756005A4 (de) 1998-09-09
JP3914272B2 (ja) 2007-05-16
US6130060A (en) 2000-10-10
CA2180103A1 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
ATE290591T1 (de) Für adseverin kodierendes gen
NO179253C (no) Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
DE3855084D1 (de) Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist
DE69615055D1 (de) Gene kodierend für ultrathermostabile proteasen
ATE334195T1 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
AU8649698A (en) Cell cycle-regulating proteins
KR870010193A (ko) 인체 췌장 엘라스타제 i
EP0546087A4 (de)
HK1021983A1 (en) Protein participating in activation of nitrile hy dratase and gene encoding the same
ATE315644T1 (de) Für das igg-fc-bindende protein kodierendes gen
DE69022901D1 (de) Streptokinase-Proteine, entsprechende Gene, entsprechende Plasmide und Verfahren zu deren Herstellung.
ATE210181T1 (de) Gen für hyperthermostabile protease
DE3572843D1 (en) Site-specific proteolysis by renin
DK0387646T3 (da) Achromobacter-protease I-gen og genprodukt deraf
ATE346941T1 (de) Protein-disulfidisomerase-gen eines methylotrophen hefestammes
EP1013665A4 (de) Neue polypeptide mit wasserkanalaktivität und dna sequenzen
EP0845536A3 (de) Protein mit Ethylendiamine-N,N'-Dibarnsteinsäure: Ethylendiamin Lyase Aktivität und dafür kodierendes Gen
EP1780275A4 (de) Polypeptid mit einer delta-5-fettsäure-unsättigungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon
AU7871101A (en) Nucleic acids and proteins showing increased expression dose under salt stress

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties